Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

@article{Skinner2014EfficacySA,
  title={Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.},
  author={S. Rachel Skinner and Anne Szarewski and Barbara Romanowski and Suzanne Marie Garland and Eduardo Lazcano-Ponce and J. Navarro Salmer{\'o}n and Maria Rowena Del Rosario-Raymundo and Ren{\'e} H. M. Verheijen and Swee Chong Quek and Daniel Pereira da Silva and Henry Charles Kitchener and Kah Leng Fong and C{\'e}line Bouchard and Deborah M Money and Arunachalam Ilancheran and Margaret E. Cruickshank and Myron J. Levin and Archana Chatterjee and Jack T. Stapleton and Mark G. Martens and Wim G. V. Quint and Marie-Pierre M David and Doroth{\'e}e Meric and Karin Hardt and Dominique J Descamps and Brecht Geeraerts and Frank Struyf and Gary O. Dubin},
  journal={Lancet},
  year={2014},
  volume={384 9961},
  pages={2213-27}
}
BACKGROUND Although adolescent girls are the main population for prophylactic human papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also be vaccinated. We report data from the interim analysis of the ongoing VIVIANE study, the aim of which is to assess the efficacy, safety, and immunogenicity of the HPV 16/18 AS04-adjuvanted vaccine in adult women. METHODS In this phase 3, multinational, double-blind, randomised controlled trial, we randomly assigned… CONTINUE READING
30 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Effi cacy of the human papillomavirus ( HPV ) - 16 / 18 AS 04 - adjuvanted vaccine in women aged 15 - 25 years with and without serological evidence of previous exposure to HPV - 16 / 18

  • F Bray, B Carstensen, H Møller
  • Int J Cancer
  • 2012

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

  • M man
  • J Natl Cancer Inst
  • 2010

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey

  • S de Sanjosé, WGV Quint, L Alemany
  • Lancet Oncol
  • 2010

Similar Papers

Loading similar papers…